ALB and neoplasm: Recently developed formulations of anticancer compounds, such as PTX bound to albumin nanoparticles, have shown several potential advantages over free-form drugs, such as (i) protecting drugs from degradation before they reach their target, (ii) increasing tumor drug absorption, (iii) allowing better control of the timing and distribution of drugs on tumor tissue, and (iv) the prevention of drug interaction with normal cells, reducing systemic toxicity overall.